



FOR IMMEDIATE RELEASE

TSX: BMR

NOTICE OF BRADMER PHARMACEUTICALS CONFERENCE CALL

Toronto, Ontario – March 5, 2008 – Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, will release its year end fiscal results for 2007 on March 12, 2008, at 7:00 AM Eastern Time. The announcement will be followed by a conference call at 10:00 AM Eastern Time hosted by Mr. Alan M. Ezrin, President and Chief Executive Officer and Mr. Paul Van Damme, Chief Financial Officer to discuss the Company's financial results and corporate developments.

CONFERENCE CALL DETAILS

DATE: March 12, 2008
TIME: 10:00 AM Eastern Time
DIAL IN NUMBER: 416-644-3420 or 800-594-3790
TAPED REPLAY: 416-640-1917 or 877-289-8525
REFERENCE NUMBER: 21265174

A live audio webcast of the conference call, complete with a slide presentation, will be available by visiting the Company's website at www.bradmerpharma.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. The webcast will be archived for 90 days.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US\$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information contact:

Bradmer Pharmaceuticals Inc.
Mr. Brian Brohman
Chief Business Officer
Phone: (416) 361-6058 (Ext. 804)
E-mail: bbrohman@bradmerpharma.com
Internet: www.bradmerpharma.com

Investor Relations
Ross Marshall
The Equicom Group Inc.
Phone: (416) 815-0700 (Ext. 238)
Fax: (416) 815-0080
E-mail: rmarshall@equicomgroup.com